For instance, the RECOVERY trial found that tocilizumab improved the clinical outcomes of COVID-19 patients with hypoxia (oxygen saturation < 92%) and CRP levels ≥ 7.5 mg/dL (17). The gene discussed is CRP; the disease is COVID-19.